文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

代谢相关脂肪性肝病患者的肠道微生物特征。

Characteristics of gut microbiota in patients with metabolic associated fatty liver disease.

机构信息

Department of Gastroenterology, Shenzhen Hospital of Southern Medical University, Shenzhen, Guangdong, China.

Department of Liver Disease Center, Shenzhen Hospital of Southern Medical University, Shenzhen, Guangdong, China.

出版信息

Sci Rep. 2023 Jun 20;13(1):9988. doi: 10.1038/s41598-023-37163-4.


DOI:10.1038/s41598-023-37163-4
PMID:37340081
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10281992/
Abstract

Metabolic associated fatty liver disease (MAFLD) is rising in incidence and is an increasingly common cause of cirrhosis and hepatocellular carcinoma (HCC). Alterations in the gut microbiota have been shown to correlate with the development and progression of MAFLD. However, little is known regarding differences in the gut microbiomes of MAFLD patients and healthy cohorts, and subgroups at the abnormal activity of hepatic enzymes in China. In this study, we enrolled 81 MAFLD patients and 25 healthy volunteers. The fecal microbiota was assessed using 16S rRNA gene sequencing and metagenomic sequencing. The results suggested that Ruminococcus obeum and Alistipes were most enriched in healthy individuals when compared with MAFLD patients. Microbe-set Enrichment Analysis (MSEA) results showed Dorea, Lactobacillus and Megasphaera are enriched in MAFLD group. We also found that Alistipes has negatively related to serum glucose (GLU), gamma-glutamyl transferase (GGT), and alanine aminotransferase (ALT). Moreover, the abundance of Dorea was found to be significantly overrepresented in the MAFLD patients and the degree of enrichment increased with the increasing abnormal liver enzyme. An increase in Dorea, combined with decreases in Alistipes appears to be characteristic of MAFLD patients. Further study of microbiota may provide a novel insight into the pathogenesis of MAFLD as well as a novel treatment strategy.

摘要

代谢相关脂肪性肝病(MAFLD)的发病率正在上升,是肝硬化和肝细胞癌(HCC)日益常见的病因。肠道微生物群的改变已被证明与 MAFLD 的发生和进展相关。然而,对于 MAFLD 患者和健康队列之间、中国肝酶异常活性的亚组之间的肠道微生物组的差异知之甚少。在这项研究中,我们招募了 81 名 MAFLD 患者和 25 名健康志愿者。使用 16S rRNA 基因测序和宏基因组测序评估粪便微生物群。结果表明,与 MAFLD 患者相比,瘤胃球菌属(Ruminococcus obeum)和双歧杆菌属(Alistipes)在健康个体中最为丰富。微生物集富集分析(MSEA)结果表明,多尔菌属(Dorea)、乳杆菌属(Lactobacillus)和巨球形菌属(Megasphaera)在 MAFLD 组中富集。我们还发现,双歧杆菌属(Alistipes)与血清葡萄糖(GLU)、γ-谷氨酰转移酶(GGT)和丙氨酸氨基转移酶(ALT)呈负相关。此外,多尔菌属(Dorea)在 MAFLD 患者中的丰度明显过高,且随着异常肝酶的增加,其富集程度也随之增加。Dorea 的增加,结合 Alistipes 的减少,似乎是 MAFLD 患者的特征。对微生物组的进一步研究可能为 MAFLD 的发病机制以及新的治疗策略提供新的见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7385/10281992/a0d51a1a545b/41598_2023_37163_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7385/10281992/ab119b67650f/41598_2023_37163_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7385/10281992/12e8c0807bbb/41598_2023_37163_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7385/10281992/dcb7832dfdad/41598_2023_37163_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7385/10281992/198860165dc6/41598_2023_37163_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7385/10281992/7464a7e2c015/41598_2023_37163_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7385/10281992/4735f93cd26b/41598_2023_37163_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7385/10281992/a0d51a1a545b/41598_2023_37163_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7385/10281992/ab119b67650f/41598_2023_37163_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7385/10281992/12e8c0807bbb/41598_2023_37163_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7385/10281992/dcb7832dfdad/41598_2023_37163_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7385/10281992/198860165dc6/41598_2023_37163_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7385/10281992/7464a7e2c015/41598_2023_37163_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7385/10281992/4735f93cd26b/41598_2023_37163_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7385/10281992/a0d51a1a545b/41598_2023_37163_Fig7_HTML.jpg

相似文献

[1]
Characteristics of gut microbiota in patients with metabolic associated fatty liver disease.

Sci Rep. 2023-6-20

[2]
Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.

Biomolecules. 2021-12-31

[3]
Non-alcoholic fatty liver disease in patients with morbid obesity: the gut microbiota axis as a potential pathophysiology mechanism.

J Gastroenterol. 2024-4

[4]
Ecological shifts of salivary microbiota associated with metabolic-associated fatty liver disease.

Front Cell Infect Microbiol. 2023

[5]
Altered gut microbiome associated with metabolic-associated fatty liver disease in Chinese children.

Clin Nutr. 2024-1

[6]
Mapping the human oral and gut fungal microbiota in patients with metabolic dysfunction-associated fatty liver disease.

Front Cell Infect Microbiol. 2023

[7]
Alterations in gut microbiome and metabolomics in chronic hepatitis B infection-associated liver disease and their impact on peripheral immune response.

Gut Microbes. 2023

[8]
Characterization of Gut Microbiome in Korean Patients with Metabolic Associated Fatty Liver Disease.

Nutrients. 2021-3-21

[9]
Metagenomic identification of gut microbiota distribution on the colonic mucosal biopsy samples in patients with non-alcoholic fatty liver disease.

Gene. 2022-7-30

[10]
Distinctive gut microbial dysbiosis between chronic alcoholic fatty liver disease and metabolic-associated fatty liver disease in mice.

Exp Ther Med. 2021-5

引用本文的文献

[1]
Consecutive fecal microbiota transplantation for metabolic dysfunction-associated steatotic liver disease: a randomized controlled trial.

Gut Microbes. 2025-12

[2]
Dissecting the Genetic Correlations and Causal Effects of Gut Microbiota on Pan-Cancer Phenotype: Driven by Common Dietary Preferences.

Food Sci Nutr. 2025-7-28

[3]
Gut microbiota in non-alcoholic fatty liver disease: Pathophysiology, diagnosis, and therapeutics.

World J Hepatol. 2025-6-27

[4]
Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease in Rats via Gut Microbiota Remodeling and Inflammatory Suppression.

Nutrients. 2025-6-16

[5]
Epithelial barrier hypothesis in the context of nutrition, microbial dysbiosis, and immune dysregulation in metabolic dysfunction-associated steatotic liver.

Front Immunol. 2025-5-14

[6]
Unlocking the gut-liver axis: microbial contributions to the pathogenesis of metabolic-associated fatty liver disease.

Front Microbiol. 2025-4-25

[7]
Gut microbiome composition and metabolic activity in metabolic-associated fatty liver disease.

Virulence. 2025-12

[8]
From Dysbiosis to Hepatic Inflammation: A Narrative Review on the Diet-Microbiota-Liver Axis in Steatotic Liver Disease.

Microorganisms. 2025-1-23

[9]
Dietary Influences on Gut Microbiota and Their Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

Nutrients. 2024-12-31

[10]
Appearance of green tea compounds in plasma following acute green tea consumption is modulated by the gut microbiome in mice.

Microbiol Spectr. 2025-2-4

本文引用的文献

[1]
The Role of the Gut-Liver Axis in Metabolic Dysfunction-Associated Fatty Liver Disease.

Front Immunol. 2021

[2]
Compositional alterations of gut microbiota in nonalcoholic fatty liver disease patients: a systematic review and Meta-analysis.

Lipids Health Dis. 2021-2-26

[3]
Mechanisms of Non-Alcoholic Fatty Liver Disease in the Metabolic Syndrome. A Narrative Review.

Antioxidants (Basel). 2021-2-10

[4]
Clinical utility of the MAFLD definition.

J Hepatol. 2021-4

[5]
Microbe-set enrichment analysis facilitates functional interpretation of microbiome profiling data.

Sci Rep. 2020-12-8

[6]
Pathophysiological mechanisms underlying MAFLD.

Diabetes Metab Syndr. 2020

[7]
A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.

J Hepatol. 2020-7

[8]
Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders.

Nat Rev Gastroenterol Hepatol. 2020-3-9

[9]
The role of gut microbiota in mediating obesity and diabetes mellitus.

Eur Rev Med Pharmacol Sci. 2020-2

[10]
Characteristics of intestinal bacteria with fatty liver diseases and cirrhosis.

Ann Hepatol. 2019-9-13

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索